TNGX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Tango Therapeutics Inc (TNGX) does not currently present a strong buy opportunity for a beginner investor with a long-term strategy. While the stock has received positive analyst ratings and price target increases, the technical indicators are mixed, and the financial performance shows significant net income and EPS declines despite revenue growth. Additionally, there are no recent news catalysts or strong trading signals to support an immediate purchase. For now, it is better to hold off on investing in this stock.
The MACD is negative and expanding, indicating bearish momentum. RSI is neutral at 44.8, providing no clear signal. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), but the stock is trading near a key support level of 11.981. Pre-market price is down 1.13%, suggesting weak sentiment.
Analysts have raised price targets, with Piper Sandler increasing the target to $14 and Stifel initiating coverage with a $15 target. The company's drug pipeline, particularly vopimetostat, has potential for significant future revenue.
No recent news or event-driven catalysts. Financial performance shows a sharp decline in net income and EPS despite revenue growth. The stock has a 50% chance of declining over the next week and month based on historical patterns.
In Q3 2025, revenue increased by 363.61% YoY to $53.81M, but net income dropped by -154.46% YoY to $15.88M, and EPS fell by -148.15% YoY to 0.13. Gross margin remains strong at 100%.
Analysts are bullish, with Piper Sandler raising the price target to $14 and Stifel initiating coverage with a $15 target. Both firms highlight the potential of the company's drug pipeline, particularly vopimetostat, as a key growth driver.
